Organisation paid for research Program year 2025 Source: CMS Open Payments

Focus Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$84,918

41 payments

Through program year 2025, Focus Clinical Research is reported as receiving $84,918 in research payments, across 41 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $48,118 33
2024 Research $1,000 1
2023 Research $35,800 7

Breakdown

Who paid Research payments · program years 2023–2025
  1. Amgen Inc. $37,498 2 payments
  2. Mylan Inc. $19,277 6 payments
  3. Cue Health Inc. $15,024 1 payment
  4. Boehringer Ingelheim Pharma GmbH & Co.KG $6,677 1 payment
  5. Boehringer Ingelheim International GmbH $3,013 24 payments
  6. E.R. Squibb & Sons, L.L.C. $2,499 1 payment
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $930 6 payments
Studies the money was for Research payments · program years 2023–2025
  1. A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity $27,540 1 payment
  2. Mr-100A-01-Td-3001-A Phase 3, Multicenter, Open-Label, Single Arm Study of Mr-100A-01 in Women of Childbearing Potential to Evaluate Contraceptive Efficacy and Safety $19,277 6 payments
  3. Strep $15,024 1 payment
  4. A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) $9,959 1 payment
  5. A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. $8,274 13 payments
  6. A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive HCM) $2,499 1 payment
  7. A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD $2,346 18 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record